Medicamentos, con mayor alza de precios en 6 años

The article highlights a significant surge in pharmaceutical prices in Mexico, with specific categories such as analgesics and anti-inflammatories reaching multi-year highs. This inflationary trend, driven by rising costs of raw materials, packaging, and transportation, has outpaced general inflation. Industry leaders express deep concern that these escalating production costs, combined with new government labor policies, threaten the viability of small and medium-sized enterprises that dominate this sector. Despite these financial pressures, generic manufacturers have attempted to absorb some cost increases to remain competitive and accessible to consumers, who increasingly prefer affordable options. This consumer behavior has contributed to substantial growth in the market share of generic drugs over recent years. However, distributors and producers warn that the current economic climate is precarious, potentially leading to business closures if the balance between cost recovery and social accessibility is not carefully managed. This development is highly relevant to open data initiatives because it underscores the critical need for transparent, accessible, and timely statistical data regarding healthcare markets. Open data can empower citizens to track price variations, understand the impact of inflation on essential goods, and hold institutions accountable. Furthermore, it facilitates better analysis for policymakers to design equitable health policies and supports researchers in monitoring the sustainability of local pharmaceutical industries amidst economic volatility.

Source: cuartopoder.mx
Published on 2023-01-16

Medicamentos, con mayor alza de precios en 6 años

Related news